Search
Mifamurtide
go.drugbank.com/drugs/DB13615ApprovedInvestigationalAlso called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP).
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway.
Isoflavone
go.drugbank.com/drugs/DB12007ApprovedInvestigationalWithdrawnIsoflavone is found as one of constituents in oral over-the-counter dietary supplements indicated for improved bone mass density and body fat regulation.
Sarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigationalcascades of IL-6. … Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersSecukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque
Products: COSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 150MG/ML, Fraizeron 150mg/ml solution for injection in pre-filled penNirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[A234224,A234229,A234234] In 2020, Pfizer was investigating another potential treatment for SARS-CoV-2, [PF-07304814]. … Nirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CL<sup>PRO</sup>) inhibitor that is the subject of clinical trial NCT04756531.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesAsciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigationalAsciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). … [L39005] It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wild-type BCR-ABL1.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesThonzylamine
go.drugbank.com/drugs/DB11235ApprovedThonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with DB04837 or DB00388 for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.
Mixtures: Nasopen PE, Poly Hist PDDiosmin
go.drugbank.com/drugs/DB08995ApprovedInvestigationalDiosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.[A232890,T840,L33040]
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2C9 InhibitorsCetalkonium
go.drugbank.com/drugs/DB11583ApprovedWithdrawn[L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113]